Literature DB >> 30518559

Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.

Rajendra Raut1, Kizzmekia S Corbett1, Rashika N Tennekoon2, Sunil Premawansa3, Ananda Wijewickrama4, Gayani Premawansa5, Piotr Mieczkowski6, Claudia Rückert7, Gregory D Ebel7, Aruna D De Silva2, Aravinda M de Silva8.   

Abstract

The four dengue virus (DENV) serotypes are mosquito-borne flaviviruses of humans. The interactions between DENVs and the human host that lead to asymptomatic, mild, or severe disease are poorly understood, in part, because laboratory models are poor surrogates for human DENV disease. Virologists are interested in how the properties of DENVs replicating in people compare with virions propagated on laboratory cell lines, which are widely used for research and vaccine development. Using clinical samples from a DENV type 1 epidemic in Sri Lanka and new ultrasensitive assays, we compared the properties of DENVs in human plasma and after one passage on laboratory cell lines. DENVs in plasma were 50- to 700-fold more infectious than cell culture-grown viruses. DENVs produced by laboratory cell lines were structurally immature and hypersensitive to neutralization by human antibodies compared with DENVs circulating in people. Human plasma and cell culture-derived virions had identical genome sequences, indicating that these phenotypic differences were due to the mature state of plasma virions. Several dengue vaccines are under development. Recent studies indicate that vaccine-induced antibodies that neutralized DENVs in cell culture assays were not sufficient for protecting people from DENV infections. Our results about structural differences between DENVs produced in humans versus cell lines may be key to understanding vaccine failure and developing better models for vaccine evaluation.

Entities:  

Keywords:  antibody; dengue; maturation; neutralization; structure

Mesh:

Substances:

Year:  2018        PMID: 30518559      PMCID: PMC6320508          DOI: 10.1073/pnas.1812055115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

Authors:  Richard J Kuhn; Wei Zhang; Michael G Rossmann; Sergei V Pletnev; Jeroen Corver; Edith Lenches; Christopher T Jones; Suchetana Mukhopadhyay; Paul R Chipman; Ellen G Strauss; Timothy S Baker; James H Strauss
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

2.  The structural basis for serotype-specific neutralization of dengue virus by a human antibody.

Authors:  Ee Ping Teoh; Petra Kukkaro; En Wei Teo; Angeline P C Lim; Tze Tong Tan; Andy Yip; Wouter Schul; Myint Aung; Victor A Kostyuchenko; Yee Sin Leo; Soh Ha Chan; Kenneth G C Smith; Annie Hoi Yi Chan; Gang Zou; Eng Eong Ooi; D Michael Kemeny; Grace K Tan; Jowin K W Ng; Mah Lee Ng; Sylvie Alonso; Dale Fisher; Pei-Yong Shi; Brendon J Hanson; Shee-Mei Lok; Paul A MacAry
Journal:  Sci Transl Med       Date:  2012-06-20       Impact factor: 17.956

3.  Association of the pr peptides with dengue virus at acidic pH blocks membrane fusion.

Authors:  I-M Yu; H A Holdaway; P R Chipman; R J Kuhn; M G Rossmann; J Chen
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

Review 4.  Degrees of maturity: the complex structure and biology of flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

Review 5.  Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection.

Authors:  Maria G Guzman; Mayling Alvarez; Scott B Halstead
Journal:  Arch Virol       Date:  2013-03-08       Impact factor: 2.574

6.  Recognition determinants of broadly neutralizing human antibodies against dengue viruses.

Authors:  Alexander Rouvinski; Pablo Guardado-Calvo; Giovanna Barba-Spaeth; Stéphane Duquerroy; Marie-Christine Vaney; Carlos M Kikuti; M Erika Navarro Sanchez; Wanwisa Dejnirattisai; Wiyada Wongwiwat; Ahmed Haouz; Christine Girard-Blanc; Stéphane Petres; William E Shepard; Philippe Desprès; Fernando Arenzana-Seisdedos; Philippe Dussart; Juthathip Mongkolsapaya; Gavin R Screaton; Félix A Rey
Journal:  Nature       Date:  2015-01-12       Impact factor: 49.962

7.  Infectious dengue vesicles derived from CD61+ cells in acute patient plasma exhibited a diaphanous appearance.

Authors:  Alan Yi-Hui Hsu; Shang-Rung Wu; Jih-Jin Tsai; Po-Lin Chen; Ya-Ping Chen; Tsai-Yun Chen; Yu-Chih Lo; Tzu-Chuan Ho; Meed Lee; Min-Ting Chen; Yen-Chi Chiu; Guey Chuen Perng
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

8.  A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis.

Authors:  Leslie Goo; Laura A VanBlargan; Kimberly A Dowd; Michael S Diamond; Theodore C Pierson
Journal:  PLoS Pathog       Date:  2017-02-16       Impact factor: 6.823

Review 9.  The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis.

Authors:  Peifang Sun; Tadeusz J Kochel
Journal:  ScientificWorldJournal       Date:  2013-02-10

10.  Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.

Authors:  Kimberly A Dowd; Christina R DeMaso; Theodore C Pierson
Journal:  MBio       Date:  2015-11-03       Impact factor: 7.867

View more
  28 in total

1.  Insights from direct studies on human dengue infections.

Authors:  Scott B Halstead
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-13       Impact factor: 11.205

Review 2.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

3.  Dengue vaccines: the road to failure or to success?

Authors:  Stanley A Plotkin
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

4.  Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.

Authors:  Rita E Chen; Brittany K Smith; John M Errico; David N Gordon; Emma S Winkler; Laura A VanBlargan; Chandni Desai; Scott A Handley; Kimberly A Dowd; Emerito Amaro-Carambot; M Jane Cardosa; Carlos A Sariol; Esper G Kallas; Rafick-Pierre Sékaly; Nikos Vasilakis; Daved H Fremont; Stephen S Whitehead; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2021-10-04       Impact factor: 31.316

Review 5.  Protective and enhancing interactions among dengue viruses 1-4 and Zika virus.

Authors:  Leah C Katzelnick; Sandra Bos; Eva Harris
Journal:  Curr Opin Virol       Date:  2020-09-24       Impact factor: 7.090

6.  Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection.

Authors:  Sandra Henein; Cameron Adams; Matthew Bonaparte; Janice M Moser; Alina Munteanu; Ralph Baric; Aravinda M de Silva
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

7.  Generation of Mature DENVs via Genetic Modification and Directed Evolution.

Authors:  Longping V Tse; Rita M Meganck; Stephanie Dong; Lily E Adams; Laura J White; Michael L Mallory; Ramesh Jadi; Aravinda M de Silva; Ralph S Baric
Journal:  mBio       Date:  2022-04-28       Impact factor: 7.786

8.  TLR2 on blood monocytes senses dengue virus infection and its expression correlates with disease pathogenesis.

Authors:  José A Aguilar-Briseño; Vinit Upasani; Bram M Ter Ellen; Jill Moser; Mindaugas Pauzuolis; Mariana Ruiz-Silva; Sothy Heng; Denis Laurent; Rithy Choeung; Philippe Dussart; Tineke Cantaert; Jolanda M Smit; Izabela A Rodenhuis-Zybert
Journal:  Nat Commun       Date:  2020-06-23       Impact factor: 14.919

9.  Potency and breadth of human primary ZIKV immune sera shows that Zika viruses cluster antigenically as a single serotype.

Authors:  Chad D Nix; Jonathan Salberg; Felicity J Coulter; Bettie W Kareko; Zoe L Lyski; Brian L Booty; William B Messer
Journal:  PLoS Negl Trop Dis       Date:  2020-04-13

Review 10.  Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?

Authors:  Lucas Wilken; Guus F Rimmelzwaan
Journal:  Pathogens       Date:  2020-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.